← All organizations
Highest phase reached
Phase 3
Timeline
2000s
- Jun 1, 2001
R-Pharm— Founded
- Oct 16, 2007
ixabepilone— NDA Secondary Org
2010s
- Mar 1, 2019
Tarsa Therapeutics, Inc.— Acquired
Drugs by trial phase (49 distinct, 70 trials)
Phase 3 (25 own, 1 via acquisition)
Phase 2 (11 own, 0 via acquisition)
Phase 1 (12 own, 0 via acquisition)
Indications
Studied for
- Alcoholism
- Arthritis
- Arthritis, Gouty
- Arthritis, Rheumatoid
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Coronavirus Infections
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Gout
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Hypertension
- Infarction
- Inflammation
- Liver Diseases
- Lung Neoplasms
- Myocardial Infarction
- Necrosis
- Neoplasms
- Pancreatic Neoplasms
- Pericarditis
- Pneumonia
- Pneumonia, Bacterial
- Schnitzler Syndrome
- Severe Acute Respiratory Syndrome
- ST Elevation Myocardial Infarction
- Stomach Neoplasms
- Syndrome
- Urinary Bladder, Overactive
- Urticaria
- Vasculitis
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT07206043OfficialPhase 1Dec 3, 2024
- NCT07206043Lead sponsorPhase 1Dec 3, 2024
- NCT06320353Lead sponsorPhase 3Sep 27, 2023
- NCT06320353OfficialPhase 3Sep 27, 2023
- NCT06440746Lead sponsorPhase 2/Phase 3Aug 23, 2023
- NCT06440746CollaboratorPhase 2/Phase 3Aug 23, 2023
- NCT06440746OfficialPhase 2/Phase 3Aug 23, 2023
- NCT06307093Lead sponsorPhase 1Mar 1, 2023
- NCT06307093OfficialPhase 1Mar 1, 2023
- NCT05432960Lead sponsorPhase 3Aug 31, 2022
- NCT05432960Study directorPhase 3Aug 31, 2022
- NCT05432960OfficialPhase 3Aug 31, 2022
- NCT05107934Study directorPhase 2/Phase 3Mar 1, 2022
- NCT05107934Lead sponsorPhase 2/Phase 3Mar 1, 2022
- NCT05190991Lead sponsorPhase 2Oct 5, 2021
Details
- Founded
- Moscow, RU Jun 1, 2001
- Last known activity
- Dec 3, 2024